Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 312 participants.

Also called NCT02836873

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 312 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02836873
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, France, Japan, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02836873. Randomized; triple masking; primary purpose treatment. Start 2016-09-23 (actual); primary completion 2018-01-11 (actual). Results posted on 2021-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Bexagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct02836873
Content hash
e6a322382fb77aae16d26643dc27a8b9f3b05519faf5146b4248b97f1b4b0361